@humanigen Management should furthermore be very open to:
1. Fair buyout offers / sell of the company to ensure further development of lenzilumab, the hard work that went into it & maximize shareholder value.
2. Reduced salary to keep important staff employed.
3. Sell Lenzilumab off-label.
"we look forward to results of the NIH’s ACTIV-5/BET-B study of lenzilumab, which is designed to confirm this approach,” stated Dr. Cameron Durrant, Chairman and CEO, Humanigen $hgen